Search

everythinglearnresearchcommunity

for

Search:↓

Most people with alopecia areata have nail changes, which are common but don't greatly affect their quality of life.

Alopecia patients struggle with emotions and stress, and improving emotional intelligence may help manage hair loss.

Tofacitinib improves nail conditions in patients with severe hair loss and does not affect hair regrowth.

JAK inhibitors help hair regrowth in alopecia areata but have a high risk of side effects.

Doctors in the Middle East need better treatments and more knowledge about new therapies for hair loss condition Alopecia Areata.

Scalp cooling can help prevent chemotherapy-induced hair loss with a 50-90% success rate and is safe for patients.

Regrowing scalp hair improves quality of life and reduces anxiety and depression in severe alopecia areata patients.

Patients with alopecia areata may have lower vitamin D levels than healthy people.

The combination of vitamin D analogues with potent steroids is a favorable treatment for alopecia areata with fewer side effects.

Intravenous corticosteroid therapy is effective for long-term hair regrowth in alopecia areata, and a scoring system helps predict treatment success and relapse.

Tofacitinib was effective for severe, treatment-resistant hair loss without side effects.

Ruxolitinib and tofacitinib are effective and safe for treating severe alopecia areata.

Too much epidermal growth factor can cause hair loss.

Skin disease activity scores can help decide when skin symptoms no longer affect the quality of life in patients with mild dermatomyositis.

Increasing the dose of baricitinib to 4 mg helps more patients with severe alopecia areata regrow hair.

Certain genes on chromosomes 6, 10, 16, and 18 may increase the risk of alopecia areata.

Yellow dots are common in severe alopecia areata.

Experts recommend personalized treatment plans for best outcomes in managing Alopecia Areata.

People with alopecia areata had lower vitamin D levels, but these levels did not relate to how severe their condition was.

Hair loss from alopecia areata and androgenetic alopecia moderately affects the quality of life, especially in younger patients and those with long-term hair loss, impacting both their physical and emotional well-being.

People with alopecia have shorter hair follicles and more c-kit, a stem cell factor receptor, which could predict how the condition progresses.

A mix of methotrexate, corticosteroids, and topical minoxidil effectively treated severe total body hair loss, but caused stretch marks and needs long-term monitoring.

Alopecia areata patients, especially women with nail issues or atopic diseases, are at higher risk for other autoimmune diseases.

The paper concludes that the new medication baricitinib needs further testing in a more diverse group of patients with alopecia areata.

Severe and early hair loss may indicate a higher risk of heart disease.

Women with type D personality and PCOS experience more stress and use less effective coping strategies.

Hair loss in Saudi Arabia causes a low psychosocial impact, with less effect on those without a family history of hair loss.

Alopecia Areata is linked to a higher risk of several diseases, which vary with age and sex.

PRP is an effective and safe treatment for alopecia areata.

More severe hair loss worsens quality of life in men.